TP53 and neoplasm: The initial molecular evaluation of patient-derived tumor samples was characterized by higher FGFR3 expression in low-grade tumor lines in comparison with high-grade ones, and an equal intergroup level of both p53 protein expression and FGFR3 mutation rate.